Aliskiren for the treatment of essential hypertension under real-life practice conditions: Design and baseline data of the prospective 3A registry

International Journal of Clinical Practice

Volumn 66, Issue 3, 2012, Pages 251-261

  Zeymer, U ^a,b   Dechend, R ^c   Deeg, E ^b   Kaiser, E ^d   Senges, J ^b   Pittrow, D ^e   Schmieder, R ^f  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; EMPLOYMENT; ESSENTIAL HYPERTENSION; FEMALE; GERMANY; HEALTH INSURANCE; HEART FAILURE; HUMAN; HYPERTENSION; INFORMATION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; OUTPATIENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; SEX RATIO; SYSTOLIC BLOOD PRESSURE;

AGED; AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG SUBSTITUTION; DRUG UTILIZATION REVIEW; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS;

EID: 84857362756     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02893.x     Document Type: Article

References (43)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al., Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. J Am Med Ass 2003; 289: 2363-9. (Pubitemid 37430168)
2. Sharma A, Wittchen H, Kirch W, et al., High prevalence and poor control of hypertension in primary care: cross sectional study. J Hypertens 2004; 22: 479-86. (Pubitemid 38368480)
3. Löwel H, Meisinger C, Heier M, et al., Epidemiologie der arteriellen Hypertonie in Deutschland. Ausgewählte Ergebnisse bevö lkerungsrepräsentativer Querschnittstudien. Dtsch Med Wochenschr 2006; 131: 2586-91. (Pubitemid 44899498)
4. Pittrow D, Pieper L, Klotsche J, Wittchen H, eds. DETECT. Ergebnisse einer klinisch-epidemiologischen Querschnitts- und Verlaufsstudie mit 50.000 Patienten in 3.000 Hausarztpraxen. München: Elsevier, 2007.
5. Thoenes M, Tebbe U, Rosin L, et al., Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists. Clin Res Cardiol 2011; 100: 483-91.
6. MacMahon S, Peto R, Cutler J, et al., Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74. (Pubitemid 20106689)
7. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9.
8. Heisler M, Hogan MM, Hofer TP, et al., When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation 2008; 117: 2884-92. (Pubitemid 351787069)
9. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006; 1: 221-8.
10. O'Brien E, Barton J, Nussberger J, et al., Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276-84. (Pubitemid 46143002)
11. Muhlestein JB, May HT, Bair TL, et al., Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol 2010; 106: 764-9.
12. Muhlestein JB, May HT, Bair TL, et al., Elevated plasma renin activity (PRA) is associated with adverse renal outcomes in patients with coronary artery disease (SU 089). Presentation at the World Congress of Nephrology, April 8-12, 2011, Vancouver, Canada.
13. Duggan ST, Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs 2010; 70: 2011-49.
14. Oh BH, Mitchell J, Herron JR, et al., Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-63. (Pubitemid 46400330)
15. Palatini P, Jung W, Shlyakhto E, et al., Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24: 93-103.
16. Düsing R, Baschiera F, Baek I, Brunel P. Aliskiren provides more prolonged reductions in 24-hour mean ambulatory blood pressure during treatment withdrawal than telmisartan [Poster 15.393]. Presented at the European Society of Hypertension Meeting in Milan, June 17-20, 2011. Abstract Book by Wolters Kluwer Health, Lippincott Williams & Wilkins. at (page 271).
17. Reboldi G, Gentile G, Angeli F, Verdecchia P. Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. Expert Opin Drug Metab Toxicol 2011; 7: 115-28.
18. Epstein BJ. Aliskiren and valsartan combination therapy for the management of hypertension. Vasc Health Risk Manag 2010; 6: 711-22.
19. de Cotret P, Steele A, Leclerc JM, et al., Real-life blood pressure reductions in hypertension patients treated with aliskiren. Interim results of the Canadian Anchor registry (4A.05). J Hypertens 2011 (eSuppl A); 29:e48.
20. Steele A, de Cotret PR, Hubert M, et al., EDTA: Effects of an aliskiren-based treatment on blood pressure and urinary albumin creatinine ratio in hypertensive outpatients: results of an interim analysis of the Canadian ANCHOR registry. 48th congress of European Renal Association (ERA/EDTA), June 23-26, 2011, Prague, Czech Republic NDT Plus (2011) 4 (suppl 2): doi: 10.1093/ndtplus/4.s2.45.
21. Volpe M, Tocci G, Bianchini F, et al., Use of aliskiren in a 'real-life' model of hypertension management: analysis of national Web-based drug-monitoring system in Italy. J Hypertens 2012; 30: 194-203.
22. European Medicines Agency (EMA). Rasilez (manufacturer: Novartis). Product information. (accessed November 2011).
23. Mancia G, Laurent S, Agabiti-Rosei E, et al., Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009; 18: 308-47.
24. Deutsche Hypertonie Gesellschaft-Deutsche Hochdruckliga e.V. (DHL). S2 Guideline: Treatment of Arterial Hypertension, Bonn, 2008. (accessed October 2011). 34: 481-98
25. National Institute for Clinical Excellence (NICE). Clincial Guideline CG 127 Hypertension: Full Guideline, London, August 2011. (accessed November 2011).
26. Bundesministerium für Gesundheit. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über die Înderung der Arzneimittel-Richtlinie (AM-RL) in Anlage IV [1440 A]: Therapiehinweis zu Aliskiren, vom 17. Dezember 2009. Quelle: Bundesanzeiger Nr. 56 (S. 1326) vom 14.4.2010. (accessed March 2011).
27. Verband der forschenden Arzneimittelhersteller (VfA). Registry of Non-Interventional Studies (NIS): 3A Register. (accessed October 2011).
28. Mancia G, Laurent S, Agabiti-Rosei E, et al., Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.
29. Verpooten GA, Aerts A, Coen N, et al., Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). Int J Clin Pract 2011; 65: 54-63.
30. Fortin M, Bravo G, Hudon C, et al., Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005; 3: 223-8. (Pubitemid 40806715)
31. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 2005; 365: 82-93. (Pubitemid 40082150)
32. Steckelings U, Stoppelhaar M, Sharma A, et al., HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Press 2004; 13: 80-8. (Pubitemid 38607703)
33. Silber S, Richartz BM, Goss F, et al., [Care of hypertensive patients seen by cardiologists: results of the Snapshot Hypertension Registry]. Dtsch Med Wochenschr 2007; 132: 2430-5. (Pubitemid 350204699)
34. Muller A, Schweizer J, Kirch W, Schindler C. [Current status of antihypertensive drug treatment in primary care practice at launch of the new renin inhibitor aliskiren (RASANT)]. Med Klin (Munich) 2010; 105: 155-62.
35. Mancia G, Grassi G. Impact of new clinical trials on recent guidelines on hypertension management. Ann Med 2011; 43: 124-32.
36. Neutel JM. Long-term blood pressure control: what can we do? Postgrad Med 2011; 123: 88-93.
37. Mancia G, De Backer G, Dominiczak A, et al., 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
38. Uresin Y, Taylor AA, Kilo C, et al., Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-8. (Pubitemid 351166266)
39. Oparil S, Yarows SA, Patel S, et al., Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-9. (Pubitemid 47069535)
40. Verdecchia P, Angeli F, Mazzotta G, et al., Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis 2010; 4: 193-200.
41. Pool JL, Schmieder RE, Azizi M, et al., Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20. (Pubitemid 46014059)
42. Chrysant SG, Murray AV, Hoppe UC, et al., Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Curr Med Res Opin 2010; 26: 2841-9.
43. McMurray JJV, Piit B, Latini R, et al., Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.